GRAIL Inc. (NASDAQ:GRAL) secured a positive recommendation from an advisory panel of the U.S. Food and Drug Administration (FDA) regarding the premarket approval application for its Galleri multi-cancer early detection test.
The FDA’s Molecular and Clinical Genetics Devices Panel evaluated the screening tool’s safety, efficacy, and overall benefit-to-risk ratio. The evaluation focused on utilizing the diagnostic test for adults aged 50 and older.
Committee Voting Results
During the review process, the 10-member committee cast three distinct votes.
Panelists unanimously agreed on the test’s safety profile. Furthermore, the committee members voted six to four backing the product’s clinical effectiveness.
Ultimately, the panel decided seven to two, with a single abstention, that the advantages of the Galleri test significantly outweigh its potential risks.
How The Diagnostic Test Functions
The screening tool identifies unique cancer-specific methylation signatures shared across numerous cancer types prior to any symptom onset.
Crucially, this includes detecting malignancies that currently lack standard clinical screening guidelines.
Once a positive signal is found, the diagnostic test predicts the origin of the cancer with high precision, assisting healthcare professionals in their diagnostic assessments.
The company emphasizes that Galleri serves as a supplementary tool, rather than a complete substitute for guideline-recommended cancer screenings.
Clinical Data And Future Regulatory Action
Galleri stands as the sole multi-cancer detection test backed by randomized controlled trials within its target demographic.
These trials incorporate major FDA-approved Investigational Device Exemption studies, such as PATHFINDER 2 in North America and the NHS-Galleri trial in England.
Throughout these clinical evaluations, the test identified roughly four to seven times more malignancies compared to traditional standard-of-care methods alone.
Most of these detected cancers surfaced in their initial stages, maximizing the chances for successful curative treatment while keeping false-positive rates minimal.
The FDA initially granted Galleri a Breakthrough Device designation in 2018.
GRAL Price Action: Grail shares were up 8.03% at $117.23 at the time of publication on Thursday. The stock is trading near its 52-week high of $118.84, according to Benzinga Pro data.
Photo by Wirestock Creators via Shutterstock
Login to comment